<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00113607</url>
  </required_header>
  <id_info>
    <org_study_id>CR003448</org_study_id>
    <secondary_id>ET743-OVA-301</secondary_id>
    <secondary_id>2004-005276-16</secondary_id>
    <nct_id>NCT00113607</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer</brief_title>
  <official_title>An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL/CAELYX and YONDELIS With DOXIL/CAELYX Alone in Subjects With Advanced Relapsed Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the progression-free survival (PFS) of the combination
      of trabectedin + DOXIL with DOXIL monotherapy in patients with ovarian cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label (all people know the identity of the intervention),
      randomized (study medication is assigned by chance), Phase 3 study comparing the combination
      of trabectedin + DOXIL with DOXIL monotherapy in patients with advanced ovarian cancer (who
      were previously treated and for whom first-line platinum-based chemotherapy regimen has
      failed). Approximately 650 patients will be randomly assigned to 1 of the treatment arms
      (DOXIL and DOXIL + trabectedin) over 2 years. At the time of randomization, patients will be
      stratified on the basis of platinum sensitivity of disease (sensitive or resistant) and
      baseline Eastern Cooperative Oncology Group performance status score (0 to 1 or 2. Safety
      will be evaluated on the basis of adverse events, clinical laboratory tests, physical
      examination, vital signs assessment and cardiovascular safety assessment. An interim analysis
      of overall survival will be performed in conjunction with progression-free survival analysis
      during the study. Treatment will be continued until disease progression occurred or until
      patients experienced a confirmed complete response for at least 2 cycles. Continuation of
      treatment in select individual patients beyond this study end date will be allowed if the
      investigator determined that the patient is benefiting from treatment, is eligible to receive
      further therapy, and consents to treatment. If disease progression has not occurred at
      treatment termination, then disease assessment will continue every 8 weeks until there is
      evidence of disease progression or death, or until the clinical data cutoff date, or until
      the start of first subsequent anticancer therapy, whichever is earlier.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS): Independent Radiologist Review</measure>
    <time_frame>From the date of randomization until the date of disease progression or death, as assessed for approximately 3 years</time_frame>
    <description>PFS is defined as the time between randomization and disease progression or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of randomization until the date of death, as assessed for approximately 3 years</time_frame>
    <description>Overall survival was defined as the time between the randomization and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) - Independent Radiologist Review</measure>
    <time_frame>From the date of randomization until the date of disease progression or death, as assessed for approximately 3 years</time_frame>
    <description>Percentage of participants who achieved complete response (CR) or partial response (PR) as best overall response. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR)= greater than or equal to 30% decrease in the sum of the longest diameter of target lesions and Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response: Independent Radiologist Review</measure>
    <time_frame>From the date of first documentation of response to the date of disease progression or death due to progressive disease, as assessed for approximately 3 years</time_frame>
    <description>Duration of response was defined only for participants who had complete response or partial response as best overall response. Duration of response was calculated from the date of first documentation of response (not the confirmation) to the date of disease progression or death due to progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Area Under Curve (AUC) of Trabectedin.</measure>
    <time_frame>Day 1 (Predose; 1.5 hour after start of infusion; 5 minutes, 2 hour and 6 to 20 hour after end of infusion); Day 8 (168 hour after end of infusion); and Day 15 (336 hour after end of infusion) at Cycles 1 and 2</time_frame>
    <description>Median simulated area under the curve (AUC) of a 21 day trabectedin profile of participants (of this study) administering trabectedin and doxil, calculated using the trapezoidal rule method. Simulations were based on a dataset created of 1000 participants using the posthoc parameter estimations, derived from the population pharmacokinetic analysis dataset of Trabectedin (Participants=831, with resampling). Plasma concentration-time profiles were simulated up to 504 hour post-dosing using a rich sampling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Maximum Plasma Concentration (Cmax) of Trabectedin.</measure>
    <time_frame>Day 1 (Predose; 1.5 hour after start of infusion; 5 minutes, 2 hour and 6 to 20 hour after end of infusion); Day 8 (168 hour after end of infusion); and Day 15 (336 hour after end of infusion) at Cycles 1 and 2</time_frame>
    <description>Median simulated maximum plasma concentration (Cmax) at 3 hour of a 21 day trabectedin profile of participants (of this study) administering trabectedin and doxil. The assessment of Cmax was based on a dataset created of 1000 participants using the posthoc parameter estimations, derived from the population pharmacokinetic analysis dataset of Trabectedin (participants=831, with resampling). Plasma concentration-time profiles were simulated up to 504 hour post-dosing using a rich sampling.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">672</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>DOXIL + trabectedin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination arm - Trabectedin + DOXIL: DOXIL 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks. patients will be premedicated with 20 mg dexamethasone or its equivalent IV infusion over 30 minutes prior to the DOXIL infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOXIL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monotherapy arm - DOXIL: 50 mg/m2 IV infusion over 90 minutes every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin</intervention_name>
    <description>Type=exact number, unit=mg/m2, number=1.1, form=solution, route=IV. Trabectedin will be administered over 3 hours every 3 weeks.</description>
    <arm_group_label>DOXIL + trabectedin</arm_group_label>
    <other_name>Yondelis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOXIL</intervention_name>
    <description>Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.</description>
    <arm_group_label>DOXIL + trabectedin</arm_group_label>
    <arm_group_label>DOXIL</arm_group_label>
    <other_name>CAELYX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Type=exact number, unit=mg, number=20, form=solution, route=IV. Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion.</description>
    <arm_group_label>DOXIL + trabectedin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven epithelial ovarian cancer, epithelial fallopian tube cancer, or
             primary peritoneal cancer

          -  Prior treatment with only 1 platinum based chemotherapy regimen

          -  Eastern Cooperative Oncology Group status of not more than 2

          -  Progression more than 6 months after the start of initial chemotherapy treatment

        Exclusion Criteria:

          -  Treatment with more than 1 prior chemotherapy regimen

          -  Progression within 6 months after starting initial chemotherapy

          -  Prior exposure to anthracyclines

          -  Unwilling or unable to have central venous catheter

          -  Known clinically relevant central nervous system metastasis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coeur D Alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sante Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bentleigh</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Douglas</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Leonards</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toorak Gardens</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barretos</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cerqueira Cesar</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Londrina</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santo Andre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reneca</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chartres</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villingen-Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilhelmshaven</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chai Wan</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansku</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa Poland</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow N/A</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Obninsk, Kaluga Region</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orenburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maranon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tao-Yuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poole</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/20516432</url>
    <description>Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22541893</url>
    <description>Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis.</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2005</study_first_submitted>
  <study_first_submitted_qc>June 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2005</study_first_posted>
  <results_first_submitted>June 18, 2013</results_first_submitted>
  <results_first_submitted_qc>June 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 23, 2013</results_first_posted>
  <disposition_first_submitted>April 10, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 10, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 11, 2012</disposition_first_posted>
  <last_update_submitted>June 18, 2014</last_update_submitted>
  <last_update_submitted_qc>June 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Trabectedin</keyword>
  <keyword>Yondelis</keyword>
  <keyword>Advanced Relapsed Ovarian Cancer</keyword>
  <keyword>DOXIL</keyword>
  <keyword>CAELYX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in a total of 21 countries at 124 sites worldwide.</recruitment_details>
      <pre_assignment_details>672 participants were randomized (337 in trabectedin + DOXIL arm and 335 in DOXIL arm) and out of which 9 participants were not treated. 663 participants received treatment ie, 330 participants received DOXIL and 333 received trabectedin + DOXIL.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DOXIL</title>
          <description>50 mg/m2 DOXIL administered as a 90-minute intravenous (IV) infusion, every 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Trabectedin/DOXIL</title>
          <description>30 mg/m2 DOXIL administered as a 90-minute IV infusion followed by 1.1 mg/m2 trabectedin as a 3-hour IV infusion, every 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="335">Number of randomized participants</participants>
                <participants group_id="P2" count="337">Number of randomized participants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="335"/>
                <participants group_id="P2" count="337"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Complete Response (Confirmed)</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DOXIL</title>
          <description>50 mg/m2 DOXIL administered as a 90-minute intravenous (IV) infusion, every 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Trabectedin/DOXIL</title>
          <description>30 mg/m2 DOXIL administered as a 90-minute IV infusion followed by 1.1 mg/m2 trabectedin as a 3-hour IV infusion, every 3 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="335"/>
            <count group_id="B2" value="337"/>
            <count group_id="B3" value="672"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.2" spread="10.75"/>
                    <measurement group_id="B2" value="56.8" spread="10.48"/>
                    <measurement group_id="B3" value="57.5" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="335"/>
                    <measurement group_id="B2" value="337"/>
                    <measurement group_id="B3" value="672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium-Luxemburg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Republic Of Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States Of America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS): Independent Radiologist Review</title>
        <description>PFS is defined as the time between randomization and disease progression or death.</description>
        <time_frame>From the date of randomization until the date of disease progression or death, as assessed for approximately 3 years</time_frame>
        <population>All Measurable Analysis Participants: All randomized participants who had measurable disease at baseline as assessed by the independent radiology review. Measurable disease is defined as having at least 1 lesion measured with a diameter of ≥20 mm using conventional techniques or of ≥10 mm using a spiral computerized tomography scan.</population>
        <group_list>
          <group group_id="O1">
            <title>DOXIL</title>
            <description>50 mg/m2 DOXIL administered as a 90-minute intravenous (IV) infusion, every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Trabectedin/DOXIL</title>
            <description>30 mg/m2 DOXIL administered as a 90-minute IV infusion followed by 1.1 mg/m2 trabectedin as a 3-hour IV infusion, every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS): Independent Radiologist Review</title>
          <description>PFS is defined as the time between randomization and disease progression or death.</description>
          <population>All Measurable Analysis Participants: All randomized participants who had measurable disease at baseline as assessed by the independent radiology review. Measurable disease is defined as having at least 1 lesion measured with a diameter of ≥20 mm using conventional techniques or of ≥10 mm using a spiral computerized tomography scan.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="5.5" upper_limit="7.1"/>
                    <measurement group_id="O2" value="7.3" lower_limit="5.9" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0190</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio, log</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival was defined as the time between the randomization and death</description>
        <time_frame>From the date of randomization until the date of death, as assessed for approximately 3 years</time_frame>
        <population>All Randomized Analysis Participants: all participants who were randomized to this study, independent of whether they received study medication or not</population>
        <group_list>
          <group group_id="O1">
            <title>DOXIL</title>
            <description>50 mg/m2 DOXIL administered as a 90-minute intravenous (IV) infusion, every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Trabectedin/DOXIL</title>
            <description>30 mg/m2 DOXIL administered as a 90-minute IV infusion followed by 1.1 mg/m2 trabectedin as a 3-hour IV infusion, every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival was defined as the time between the randomization and death</description>
          <population>All Randomized Analysis Participants: all participants who were randomized to this study, independent of whether they received study medication or not</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" lower_limit="17.1" upper_limit="21.5"/>
                    <measurement group_id="O2" value="22.2" lower_limit="19.3" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0835</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio, log</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) - Independent Radiologist Review</title>
        <description>Percentage of participants who achieved complete response (CR) or partial response (PR) as best overall response. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR)= greater than or equal to 30% decrease in the sum of the longest diameter of target lesions and Overall Response (OR) = CR + PR.</description>
        <time_frame>From the date of randomization until the date of disease progression or death, as assessed for approximately 3 years</time_frame>
        <population>All Randomized Analysis Participants: all participants who were randomized to this study, independent of whether they received study medication or not.</population>
        <group_list>
          <group group_id="O1">
            <title>DOXIL</title>
            <description>50 mg/m2 DOXIL administered as a 90-minute intravenous (IV) infusion, every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Trabectedin/DOXIL</title>
            <description>30 mg/m2 DOXIL administered as a 90-minute IV infusion followed by 1.1 mg/m2 trabectedin as a 3-hour IV infusion, every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) - Independent Radiologist Review</title>
          <description>Percentage of participants who achieved complete response (CR) or partial response (PR) as best overall response. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR)= greater than or equal to 30% decrease in the sum of the longest diameter of target lesions and Overall Response (OR) = CR + PR.</description>
          <population>All Randomized Analysis Participants: all participants who were randomized to this study, independent of whether they received study medication or not.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0080</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.646</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.144</ci_lower_limit>
            <ci_upper_limit>2.367</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response: Independent Radiologist Review</title>
        <description>Duration of response was defined only for participants who had complete response or partial response as best overall response. Duration of response was calculated from the date of first documentation of response (not the confirmation) to the date of disease progression or death due to progressive disease.</description>
        <time_frame>From the date of first documentation of response to the date of disease progression or death due to progressive disease, as assessed for approximately 3 years</time_frame>
        <population>All Responders (CR/PR) Analysis Participants: all participants who achieved CR or PR as best overall response during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>DOXIL</title>
            <description>50 mg/m2 DOXIL administered as a 90-minute intravenous (IV) infusion, every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Trabectedin/DOXIL</title>
            <description>30 mg/m2 DOXIL administered as a 90-minute IV infusion followed by 1.1 mg/m2 trabectedin as a 3-hour IV infusion, every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response: Independent Radiologist Review</title>
          <description>Duration of response was defined only for participants who had complete response or partial response as best overall response. Duration of response was calculated from the date of first documentation of response (not the confirmation) to the date of disease progression or death due to progressive disease.</description>
          <population>All Responders (CR/PR) Analysis Participants: all participants who achieved CR or PR as best overall response during the study.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="6.5" upper_limit="9.0"/>
                    <measurement group_id="O2" value="7.9" lower_limit="7.4" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8203</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio, log</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Area Under Curve (AUC) of Trabectedin.</title>
        <description>Median simulated area under the curve (AUC) of a 21 day trabectedin profile of participants (of this study) administering trabectedin and doxil, calculated using the trapezoidal rule method. Simulations were based on a dataset created of 1000 participants using the posthoc parameter estimations, derived from the population pharmacokinetic analysis dataset of Trabectedin (Participants=831, with resampling). Plasma concentration-time profiles were simulated up to 504 hour post-dosing using a rich sampling.</description>
        <time_frame>Day 1 (Predose; 1.5 hour after start of infusion; 5 minutes, 2 hour and 6 to 20 hour after end of infusion); Day 8 (168 hour after end of infusion); and Day 15 (336 hour after end of infusion) at Cycles 1 and 2</time_frame>
        <population>Blood samples for pharmacokinetic analysis were collected from 86 participants of this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Trabectedin/DOXIL</title>
            <description>30 mg/m2 DOXIL administered as a 90-minute IV infusion followed by 1.1 mg/m2 trabectedin as a 3-hour IV infusion, every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Median Area Under Curve (AUC) of Trabectedin.</title>
          <description>Median simulated area under the curve (AUC) of a 21 day trabectedin profile of participants (of this study) administering trabectedin and doxil, calculated using the trapezoidal rule method. Simulations were based on a dataset created of 1000 participants using the posthoc parameter estimations, derived from the population pharmacokinetic analysis dataset of Trabectedin (Participants=831, with resampling). Plasma concentration-time profiles were simulated up to 504 hour post-dosing using a rich sampling.</description>
          <population>Blood samples for pharmacokinetic analysis were collected from 86 participants of this study.</population>
          <units>ng*h/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Maximum Plasma Concentration (Cmax) of Trabectedin.</title>
        <description>Median simulated maximum plasma concentration (Cmax) at 3 hour of a 21 day trabectedin profile of participants (of this study) administering trabectedin and doxil. The assessment of Cmax was based on a dataset created of 1000 participants using the posthoc parameter estimations, derived from the population pharmacokinetic analysis dataset of Trabectedin (participants=831, with resampling). Plasma concentration-time profiles were simulated up to 504 hour post-dosing using a rich sampling.</description>
        <time_frame>Day 1 (Predose; 1.5 hour after start of infusion; 5 minutes, 2 hour and 6 to 20 hour after end of infusion); Day 8 (168 hour after end of infusion); and Day 15 (336 hour after end of infusion) at Cycles 1 and 2</time_frame>
        <population>Blood samples for pharmacokinetic analysis were collected from 86 participants of this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Trabectedin/DOXIL</title>
            <description>30 mg/m2 DOXIL administered as a 90-minute IV infusion followed by 1.1 mg/m2 trabectedin as a 3-hour IV infusion, every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Median Maximum Plasma Concentration (Cmax) of Trabectedin.</title>
          <description>Median simulated maximum plasma concentration (Cmax) at 3 hour of a 21 day trabectedin profile of participants (of this study) administering trabectedin and doxil. The assessment of Cmax was based on a dataset created of 1000 participants using the posthoc parameter estimations, derived from the population pharmacokinetic analysis dataset of Trabectedin (participants=831, with resampling). Plasma concentration-time profiles were simulated up to 504 hour post-dosing using a rich sampling.</description>
          <population>Blood samples for pharmacokinetic analysis were collected from 86 participants of this study.</population>
          <units>pg/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of the first study-related procedure until up to 30 days after administration of the last dose of study medication.</time_frame>
      <desc>Number of treated participants were analyzed for adverse events. 672 participants were randomized (337 in trabectedin + DOXIL arm and 335 in DOXIL arm), out of which 663 participants received treatment ie, 330 participants received DOXIL and 333 received trabectedin + DOXIL and were analyzed for adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Trabectedin/DOXIL</title>
          <description>30 mg/m2 DOXIL administered as a 90-minute IV infusion followed by 1.1 mg/m2 trabectedin as a 3-hour IV infusion, every 3 weeks</description>
        </group>
        <group group_id="E2">
          <title>DOXIL</title>
          <description>50 mg/m2 DOXIL administered as a 90-minute intravenous (IV) infusion, every 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Bicytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Bone Marrow Failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Electromechanical Dissociation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomatous Polyposis Coli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Aphthous Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Colonic Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Enterocutaneous Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Erosive Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Intestinal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Large Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Mechanical Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Oesophageal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Drug Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Catheter Related Complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Catheter Site Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Condition Aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hernia Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hernia Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hepatitis Cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hepatitis Toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Bacterial Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Catheter Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Catheter Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Catheter Site Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Catheter Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Central Line Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Enterocolitis Infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Erysipeloid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Helicobacter Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Herpes Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Neutropenic Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Neutropenic Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Oesophageal Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Perineal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Device Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Medical Device Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Postoperative Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Procedural Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Procedural Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Thoracic Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Carbohydrate Antigen 125 Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Gamma-Glutamyltransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to Central Nervous System</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Metastases to Soft Tissue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Oncologic Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Paraneoplastic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Grand Mal Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Syncope Vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Obstructive Uropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Genital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Melanosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Palmar-Plantar Erythrodysaesthesia Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Axillary Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Jugular Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Subclavian Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Vena Cava Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Venous Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="333" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="318" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="256" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="251" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="185" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Palmar-Plantar Erythrodysaesthesia Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Skin Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director Clinical Research Medical Leader</name_or_title>
      <organization>Janssen R&amp;D US</organization>
      <phone>908 704 5779</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

